Stay updated on Safety of PF-06939926 Gene Therapy in Duchenne Clinical Trial
Sign up to get notified when there's something new on the Safety of PF-06939926 Gene Therapy in Duchenne Clinical Trial page.

Latest updates to the Safety of PF-06939926 Gene Therapy in Duchenne Clinical Trial page
- Check3 days agoChange DetectedAdds a new consolidated long-term safety study for movaparvovec recipients (C3391003) and marks the program as Terminated with revision v3.0.2 and dates 2025-08/15. Removes the outdated 'Active, not recruiting' status and the 'Back to Top' link.SummaryDifference0.8%
- Check10 days agoChange DetectedThe page has updated the publication date of a significant research article on AAV mini-dystrophin gene therapy for Duchenne muscular dystrophy from June 27, 2025, to August 2025, and the version number has been revised from v3.0.0 to v3.0.1.SummaryDifference0.3%
- Check18 days agoChange DetectedThe web page has been updated to include a new facility name and location, along with a list of relevant publications related to gene therapy for Duchenne muscular dystrophy. The previous version's location details have been removed.SummaryDifference5%
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.0%
- Check39 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.0%
- Check47 days agoChange DetectedThe web page has removed a service alert regarding planned maintenance and updated the revision history, indicating a transition from version v2.16.8 to v2.16.10.SummaryDifference0.7%
Stay in the know with updates to Safety of PF-06939926 Gene Therapy in Duchenne Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of PF-06939926 Gene Therapy in Duchenne Clinical Trial page.